Writing for Forbes, Senior Lecturer Guadalupe Hayes-Mota '08, SM '16, MBA '16 explains how transformative strategies in global healthcare are “reshaping the pharmaceutical market dynamics.” This new method “transcends traditional financial tactics representing a fundamental shift in global health practices towards sustainable and universal access to essential medicines,” writes Hayes-Mota.
Prof. Amy Finkelstein speaks with New York Times reporter Sarah Kliff about “the impact of medical debt relief on individuals.” “The idea that maybe we could get rid of medical debt, and it wouldn’t cost that much money but it would make a big difference, was appealing,” says Finkelstein. “What we learned, unfortunately, is that it doesn’t look like it has much of an impact.”
Prof. Joseph Doyle and his colleagues are studying whether type 2 diabetes could be treated or improved by nutrition, reports Donna Eastlake for Food Navigator.
MIT researchers have discovered a protein found in human sweat that holds antimicrobial properties and can “inhibit the growth of the bacteria that causes Lyme disease,” reports Matt Fortin for NENC. The team believes this “type of protein could be put into a topical cream to make something called ‘Lyme Block’ – like sunblock, but for preventing Lyme.” "Ideally what we would love to do is give people more control over their own risk," says Principal Research Scientist Michal Tal. "And really try to develop this into a possible preventative that you could put on repellant or sunblock to protect against other elements of the outdoors that you could also protect yourself against Lyme."
Researchers from MIT and elsewhere have isolated a “protein in human sweat that protects against Lyme disease,” reports Matthew Rozsa for Salon. The researchers believe that if “properly harnessed the protein could form the basis of skin creams that either prevent the disease or treat especially persistent infections,” writes Rosza.
MIT scientists have found that a potential treatment for Alzheimer’s disease involving flickering lights and low-pitched sound could also help prevent cognitive problems after cancer treatment, reports Clare Wilson for New Scientist. The treatment is aimed at stimulating 40 Hz brainwaves, which are linked to memory processing. The results suggest targeting such “brainwaves may result in broader benefits for the brain, including increasing the activity of immune cells and, most recently, boosting its drainage system, which could help clear a toxic protein called beta-amyloid.”
Writing for Fast Company, Senior Lecturer Guadalupe Hayes-Mota '08, SM '16, MBA '16 shares methods to address the influence of AI in healthcare. “Despite these advances [of AI in healthcare], the full spectrum of AI’s potential remains largely untapped,” explains Hayes-Mota. “Systemic hurdles such as data privacy concerns, the absence of standardized data protocols, regulatory complexities, and ethical dilemmas are compounded by an inherent resistance to change within the healthcare profession. These barriers underscore the urgent need for transformative action from all stakeholders to fully harness AI’s capabilities.”
MIT Innovation Fellow Brian Deese speaks with CNBC about how the new class of weight loss drugs will impact American taxes and the federal deficit. “These drugs could touch tens of millions of Americans, that’s the good news,” says Deese. “They have the potential to reduce obesity, address diabetes and reduce the health care costs associated with that. The problem is that the scale and the cost of these drugs is so large, that it could add enormously to the federal budget.”
Senior Lecturer Guadalupe Hayes-Mota writes for Forbes about the ways AI is reshaping drug development. “In the next three years, we can anticipate a more streamlined, efficient and cost-effective drug development process, ultimately leading to faster access to life-saving drugs for patients worldwide,” Hayes-Mota writes. “This is not just an evolution; it is a revolution in healthcare powered by the intelligence of machines.”
Researchers at MIT and elsewhere have developed a machine-learning model that can identify which drugs should not be taken together, reports Politico. “The researchers built a model to measure how intestinal tissue absorbed certain commonly used drugs,” they write. “They then trained a machine-learning algorithm based on their new data and existing drug databases, teaching the new algorithm to predict which drugs would interact with which transporter proteins.”
MIT researchers have developed new technology that allows vaccines to be directly inserted into the lymph nodes to target two of the most common mutations in the KRAS gene, which cause roughly one third of all cancers, reports Jaimie Seaton for Scientific American. “The team modified the small vaccine components to include a fatty acid, which enables the vaccine to effectively hitch a ride on albumin, a common protein found throughout the body,” explains Seaton. “Albumin serves as a molecular shuttle bus, with pockets on its surface where fatty acids can bind to it.”
Researchers at MIT and elsewhere have found that while AI systems could help doctors come to the right diagnosis more often, the diagnostic gains aren’t always distributed evenly, with more improvements tied to patients with lighter skin, report Daniel Payne, Erin Schumaker, and Ruth Reader for Politico. “AI could be a powerful tool to improve care and potentially offer providers a check on their blindspots," they write. "But that doesn’t mean AI will reduce bias. In fact, the study suggests, AI could cause greater disparities in care.”
Elemind Technologies, a neuro-tech startup founded by scientists from MIT and elsewhere, is developing, “an approach that redirects brain wave through non-invasive stimulation – using sound, light, touch and electric pulses – to potentially address a range of neurological conditions in a more targeted ways than drugs,” reports Robert Weisman for The Boston Globe.
Researchers from MIT and elsewhere have developed an AI model that is capable of identifying 3 ½ times more people who are at high-risk for developing pancreatic cancer than current standards, reports Felice J. Freyer for The Boston Globe. “This work has the potential to enlarge the group of pancreatic cancer patients who can benefit from screening from 10 percent to 35 percent,” explains Freyer. “The group hopes its model will eventually help detect risk of other hard-to-find cancers, like ovarian.”
Popular Mechanics reporter Jill Waldbieser spotlights Prof. Hugh Herr and his work developing prosthetic limbs that integrate with their human hosts using a surgical technique that preserves the sensation in artificial limbs. “In the future, on the order of five years or so, we’ll be so good at this, we’ll completely restore the signals from the prosthetic to the brain and from the brain to the prosthetic, like the limb was never amputated,” says Herr.